<p>美国市场在过去一周保持平稳，但在过去 12 个月中经历了显著的 28% 增长，预计年收益将增长 16%。在这种环境下，内部持股比例高的成长型公司尤其吸引人，因为这通常表明那些最了解业务的人对其有强烈的信心。</p>
<h3>美国内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>优信 (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.8%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.1%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>100.6%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们筛选的 193 只内部持股比例高的快速成长美国公司的完整名单。</p>
<p>让我们更仔细地看看我们从筛选公司中挑选的几只股票。</p>
<h2>Enovix (ENVX)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Enovix Corporation 设计、开发并制造锂离子电池单元，业务遍及美国及国际市场，市值为 14.4 亿美元。</p>
<p><strong>运营：</strong> 公司的收入部分来自其电池/电池系统部门，收入为 3182 万美元。</p>
<p><strong>内部持股比例：</strong> 12.4%</p>
<p>Enovix 的交易价格显著低于其估计的公允价值，且增长前景强劲。预计其收入将以每年 36.3% 的速度增长，超过美国市场的平均水平。预计该公司将在三年内实现盈利，年收益增长 41.13%。最近的财务结果显示，销售额有所改善，净亏损较去年减少，尽管近期内部交易活动保持不变。Enovix 已完成股票回购计划，并为与员工持股计划相关的 6500 万美元普通股发行提交了货架注册。</p>
<ul>
<li>点击这里了解 Enovix 的细节，查看我们的详细分析未来增长报告。</li>
<li>我们的估值报告显示 Enovix 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown"/></p>
<p>截至 2026 年 5 月的 ENVX 持股结构</p>
<h2>ImmunityBio (IBRX)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ImmunityBio, Inc. 是一家生物技术公司，致力于开发和商业化下一代免疫疗法，旨在激活免疫系统以提供对癌症和传染病的长期保护，市值约为 73.4 亿美元。</p>
<p><strong>运营：</strong> 公司的收入部分主要集中在开发下一代疗法，收入为 1.1329 亿美元。</p>
<p><strong>内部持股比例：</strong> 28.6%</p>
<p>ImmunityBio 正在经历强劲的增长，预计其收入将以每年 52% 的速度增长，超过美国市场的平均水平。尽管近期股东稀释和股价波动较大，但预计该公司将在三年内实现盈利。最近在沙特阿拉伯和其他地区对 ANKTIVA 的产品批准突显了其全球扩展的存在。然而，法律挑战和对促销行为的监管审查仍然存在风险。公司的现金流持续时间不足一年，需要谨慎的财务管理。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 ImmunityBio 的表现。</li>
<li>我们编制的估值报告表明 ImmunityBio 当前的价格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 5 月的 IBRX 收益和收入增长</p>
<h2>Wealthfront (WLTH)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Wealthfront Corporation 是一家私营投资管理公司，市值为 16.2 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其资产管理部门产生收入，收入为 3.65 亿美元。</p>
<p><strong>内部持股比例：</strong> 14.2%</p>
<p>Wealthfront Corporation 最近被纳入多个 Russell 指数，突显其作为成长实体的认可，尽管其财务状况呈现出混合的局面。该公司的收入在 2026 年第四季度上升至 9614 万美元，但与去年盈利相比，净亏损为 1.3366 亿美元。尽管如此，Wealthfront 预计将在三年内实现盈利，并已启动一项 1 亿美元的股票回购计划，显示出对未来前景的信心，内部持股比例也较高。</p>
<ul>
<li>在这份增长报告中解锁我们对 Wealthfront 股票分析的全面见解。</li>
<li>在审查我们的最新估值报告后，Wealthfront 的股价可能过于乐观。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 5 月的 WLTH 收益和收入增长</p>
<h2>下一步</h2>
<ul>
<li>点击这里更仔细地查看我们筛选的 193 家内部持股比例高的快速成长美国公司名单。</li>
<li>寻找新视角？癌症的终结？这 31 只新兴的人工智能股票正在开发技术，以便早期识别癌症和阿尔茨海默病等改变生活的疾病。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
<h3><strong>新功能：</strong> AI 股票筛选器与提醒</h3>
<p>我们的新 AI 股票筛选器每天扫描市场，以发现机会。</p>
<p>• 分红强劲的股票（收益率 3% 以上）</p>
<p>• 内部人士买入的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

ENVX

IBRX

优信

<p>美国市场在过去一年中上涨了 28%，预计年收益将增长 16%。高内部持股的成长型公司受到关注，包括优信（35.7% 的持股比例，74.1% 的收益增长）和 ImmunityBio（28.6% 的持股比例，52% 的收益增长）。Enovix 和 Wealthfront 也因其增长潜力而受到关注，尽管面临挑战。文章强调了内部持股作为信心指标的重要性，并提供了对这些公司的财务健康状况和未来前景的见解</p>

<p>The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.</p>
<div class="lb-trans"><p>美国市场在过去一周保持平稳，但在过去 12 个月中经历了显著的 28% 增长，预计年收益将增长 16%。在这种环境下，内部持股比例高的成长型公司尤其吸引人，因为这通常表明那些最了解业务的人对其有强烈的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.8%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.1%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>100.6%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>优信 (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.8%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.1%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>100.6%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 193 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们筛选的 193 只内部持股比例高的快速成长美国公司的完整名单。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>让我们更仔细地看看我们从筛选公司中挑选的几只股票。</p>
</div><h2>Enovix (ENVX)</h2>
<div class="lb-trans"><h2>Enovix (ENVX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Enovix Corporation designs, develops, and manufactures lithium-ion battery cells both in the United States and internationally, with a market cap of $1.44 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Enovix Corporation 设计、开发并制造锂离子电池单元，业务遍及美国及国际市场，市值为 14.4 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment consists of $31.82 million from its Batteries / Battery Systems division.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部分来自其电池/电池系统部门，收入为 3182 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 12.4%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 12.4%</p>
</div><p>Enovix is trading significantly below its estimated fair value, with strong growth prospects. Its revenue is expected to grow at 36.3% per year, surpassing the US market average. The company is forecasted to become profitable within three years, with earnings growing at 41.13% annually. Recent financial results show improved sales and reduced net losses compared to the previous year, although insider trading activity remains unchanged recently. Enovix has completed a share buyback program and filed a shelf registration for $65 million in common stock offerings related to an ESOP initiative.</p>
<div class="lb-trans"><p>Enovix 的交易价格显著低于其估计的公允价值，且增长前景强劲。预计其收入将以每年 36.3% 的速度增长，超过美国市场的平均水平。预计该公司将在三年内实现盈利，年收益增长 41.13%。最近的财务结果显示，销售额有所改善，净亏损较去年减少，尽管近期内部交易活动保持不变。Enovix 已完成股票回购计划，并为与员工持股计划相关的 6500 万美元普通股发行提交了货架注册。</p>
</div><ul>
<li>Click here to discover the nuances of Enovix with our detailed analytical future growth report.</li>
<li>Our valuation report here indicates Enovix may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 Enovix 的细节，查看我们的详细分析未来增长报告。</li>
<li>我们的估值报告显示 Enovix 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown"/></p>
<p>ENVX Ownership Breakdown as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 ENVX 持股结构</p>
</div><h2>ImmunityBio (IBRX)</h2>
<div class="lb-trans"><h2>ImmunityBio (IBRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing next-generation immunotherapies aimed at activating the immune system for long-lasting protection against cancer and infectious diseases, with a market cap of approximately $7.34 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ImmunityBio, Inc. 是一家生物技术公司，致力于开发和商业化下一代免疫疗法，旨在激活免疫系统以提供对癌症和传染病的长期保护，市值约为 73.4 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment is primarily focused on developing next-generation therapies, generating $113.29 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部分主要集中在开发下一代疗法，收入为 1.1329 亿美元。</p>
</div><p><strong>Insider Ownership:</strong> 28.6%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 28.6%</p>
</div><p>ImmunityBio is experiencing robust growth, with revenue forecasted to increase by 52% annually, outpacing the US market's average. Despite recent shareholder dilution and highly volatile share prices, the company is expected to achieve profitability within three years. Recent product approvals in Saudi Arabia and other regions for ANKTIVA highlight its expanding global presence. However, legal challenges and regulatory scrutiny over promotional practices present ongoing risks. The company's cash runway remains limited to less than a year, necessitating careful financial management.</p>
<div class="lb-trans"><p>ImmunityBio 正在经历强劲的增长，预计其收入将以每年 52% 的速度增长，超过美国市场的平均水平。尽管近期股东稀释和股价波动较大，但预计该公司将在三年内实现盈利。最近在沙特阿拉伯和其他地区对 ANKTIVA 的产品批准突显了其全球扩展的存在。然而，法律挑战和对促销行为的监管审查仍然存在风险。公司的现金流持续时间不足一年，需要谨慎的财务管理。</p>
</div><ul>
<li>Get an in-depth perspective on ImmunityBio's performance by reading our analyst estimates report here.</li>
<li>The valuation report we've compiled suggests that ImmunityBio's current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 ImmunityBio 的表现。</li>
<li>我们编制的估值报告表明 ImmunityBio 当前的价格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>IBRX Earnings and Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 IBRX 收益和收入增长</p>
</div><h2>Wealthfront (WLTH)</h2>
<div class="lb-trans"><h2>Wealthfront (WLTH)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Wealthfront Corporation is a privately owned investment manager with a market cap of $1.62 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Wealthfront Corporation 是一家私营投资管理公司，市值为 16.2 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its asset management segment, which accounts for $365 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其资产管理部门产生收入，收入为 3.65 亿美元。</p>
</div><p><strong>Insider Ownership:</strong> 14.2%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 14.2%</p>
</div><p>Wealthfront Corporation's recent inclusion in multiple Russell indices underscores its recognition as a growth entity, though its financials present a mixed picture. The company's revenue rose to US$96.14 million in Q4 2026, yet it recorded a net loss of US$133.66 million compared to the previous year's profit. Despite this, Wealthfront is projected to achieve profitability within three years and has initiated a US$100 million share buyback program, signaling confidence in future prospects amidst high insider ownership levels.</p>
<div class="lb-trans"><p>Wealthfront Corporation 最近被纳入多个 Russell 指数，突显其作为成长实体的认可，尽管其财务状况呈现出混合的局面。该公司的收入在 2026 年第四季度上升至 9614 万美元，但与去年盈利相比，净亏损为 1.3366 亿美元。尽管如此，Wealthfront 预计将在三年内实现盈利，并已启动一项 1 亿美元的股票回购计划，显示出对未来前景的信心，内部持股比例也较高。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Wealthfront stock in this growth report.</li>
<li>Upon reviewing our latest valuation report, Wealthfront's share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这份增长报告中解锁我们对 Wealthfront 股票分析的全面见解。</li>
<li>在审查我们的最新估值报告后，Wealthfront 的股价可能过于乐观。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth"/></p>
<p>WLTH Earnings and Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 WLTH 收益和收入增长</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Take a closer look at our Fast Growing US Companies With High Insider Ownership list of 193 companies by clicking here.</li>
<li>Searching for a Fresh Perspective? The end of cancer? These 31 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里更仔细地查看我们筛选的 193 家内部持股比例高的快速成长美国公司名单。</li>
<li>寻找新视角？癌症的终结？这 31 只新兴的人工智能股票正在开发技术，以便早期识别癌症和阿尔茨海默病等改变生活的疾病。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票筛选器与提醒</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场，以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的股票（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士买入的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

2026 年 5 月值得关注的高内部持股增长的股票